KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amneal Pharmaceuticals (AMRX) Intangibles: 2017-2024

Historic Intangibles for Amneal Pharmaceuticals (AMRX) over the last 8 years, with Dec 2024 value amounting to $732.4 million.

  • Amneal Pharmaceuticals' Intangibles fell 24.64% to $587.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $587.9 million, marking a year-over-year decrease of 24.64%. This contributed to the annual value of $732.4 million for FY2024, which is 17.75% down from last year.
  • As of FY2024, Amneal Pharmaceuticals' Intangibles stood at $732.4 million, which was down 17.75% from $890.4 million recorded in FY2023.
  • In the past 5 years, Amneal Pharmaceuticals' Intangibles registered a high of $1.3 billion during FY2020, and its lowest value of $732.4 million during FY2024.
  • For the 3-year period, Amneal Pharmaceuticals' Intangibles averaged around $906.3 million, with its median value being $890.4 million (2023).
  • Data for Amneal Pharmaceuticals' Intangibles shows a maximum YoY fell of 18.76% (in 2023) over the last 5 years.
  • Amneal Pharmaceuticals' Intangibles (Yearly) stood at $1.3 billion in 2020, then declined by 10.56% to $1.2 billion in 2021, then decreased by 6.07% to $1.1 billion in 2022, then decreased by 18.76% to $890.4 million in 2023, then fell by 17.75% to $732.4 million in 2024.